Patents by Inventor Suzanne Grothe

Suzanne Grothe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODIES SELECTIVE FOR CELLS PRESENTING EGFR AT HIGH DENSITY
    Publication number: 20200325243
    Abstract: Herein described are antibodies to epidermal growth factor receptor (EGFR) having an EGFR binding affinity that is sufficient to kill disease cells presenting EGFR at high density, but is insufficient for binding to normal cells. A therapeutic effect is thus achieved while avoiding adverse events that result from unintended binding to normal cells.
    Type: Application
    Filed: February 21, 2020
    Publication date: October 15, 2020
    Inventors: Ilia Alexandre TIKHOMIROV, Maria L. JARAMILLO, Maureen D. O'CONNOR-MCCOURT, Traian SULEA, Renald GILBERT, Bruno GAILLET, Jason BAARDSNES, Myriam BANVILLE, Suzanne GROTHE
  • Antibodies selective for cells presenting EGFR at high density
    Patent number: 10570211
    Abstract: Herein described are antibodies to epidermal growth factor receptor (EGFR) having an EGFR binding affinity that is sufficient to kill disease cells presenting EGFR at high density, but is insufficient for binding to normal cells. A therapeutic effect is thus achieved while avoiding adverse events that result from unintended binding to normal cells.
    Type: Grant
    Filed: January 20, 2012
    Date of Patent: February 25, 2020
    Assignees: GILEAD SCIENCES, INC., NATIONAL RESEARCH COUNCIL OF CANADA
    Inventors: Ilia Alexandre Tikhomirov, Maria L. Jaramillo, Maureen D. O'Connor-McCourt, Traian Sulea, Renald Gilbert, Bruno Gaillet, Jason Baardsnes, Myriam Banville, Suzanne Grothe
  • ANTIBODIES SELECTIVE FOR CELLS PRESENTING EGFR AT HIGH DENSITY
    Publication number: 20130295086
    Abstract: Herein described are antibodies to epidermal growth factor receptor (EGFR) having an EGFR binding affinity that is sufficient to kill disease cells presenting EGFR at high density, but is insufficient for binding to normal cells. A therapeutic effect is thus achieved while avoiding adverse events that result from unintended binding to normal cells.
    Type: Application
    Filed: January 20, 2012
    Publication date: November 7, 2013
    Applicants: NATIONAL RESEARCH COUNCIL OF CANADA, YM BIOSCIENCES INC.
    Inventors: Ilia Alexandre Tikhomirov, Maria L. Jaramillo, Maureen D. O'Connor-McCourt, Traian Sulea, Renald Gilbert, Bruno Gaillet, Jason Baardsnes, Myriam Banville, Suzanne Grothe